Hughey Lauren C
University of Alabama at Birmingham, 1530 3rd Avenue South, EFH 414, Birmingham, AL 35294, USA.
Dermatol Clin. 2015 Oct;33(4):819-33. doi: 10.1016/j.det.2015.05.013. Epub 2015 Aug 29.
Primary cutaneous CD30⁺ lymphoproliferative disorders (LPDs) account for approximately 25% of cutaneous lymphomas. Although these LPDs are clinically heterogeneous, they can be indistinguishable histologically. Lymphomatoid papulosis rarely requires systemic treatment; however, multifocal primary cutaneous anaplastic large cell cutaneous lymphoma and large cell transformation of mycosis fungoides are typically treated systemically. As CD30⁺ LPDs are rare, there is little published evidence to support a specific treatment algorithm. Most studies are case reports, small case series, or retrospective reviews. This article discusses various treatment choices for each of the CD30⁺ disorders and offers practical pearls to aid in choosing an appropriate regimen.
原发性皮肤CD30⁺淋巴增殖性疾病（LPDs）约占皮肤淋巴瘤的25%。虽然这些LPDs在临床上具有异质性，但在组织学上可能难以区分。淋巴瘤样丘疹病很少需要全身治疗；然而，多灶性原发性皮肤间变性大细胞皮肤淋巴瘤和蕈样肉芽肿的大细胞转化通常采用全身治疗。由于CD30⁺LPDs较为罕见，几乎没有公开的证据支持特定的治疗方案。大多数研究是病例报告、小病例系列或回顾性综述。本文讨论了每种CD30⁺疾病的各种治疗选择，并提供实用的要点以帮助选择合适的治疗方案。
